This November, Lonafarnib (ZOKINVY) received approval by the FDA as a drug to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain processing-deficient progeroid laminopathies in patients one year of age and older.

Lonafarnib, a farnesyltransferase inhibitor, is an oral medication that helps prevent the buildup of defective progerin or progerin-like protein.

This drug contains 4-azatricyclo[³,⁸]pentadeca-1(15),3,5,7,11,13-hexaene moiety in its backbone.

We have made a set of Building Blocks, which contain such part – the perfect start for your research!